Mercados españoles cerrados en 4 hrs 54 min

Merck & Co., Inc. (MRK)

NYSE - NYSE Precio demorado. Divisa en USD
Añadir a la lista de favoritos
131,75+6,23 (+4,96%)
Al cierre: 04:00PM EDT
132,56 +0,81 (+0,61%)
Antes de la apertura: 07:33AM EDT

Merck & Co., Inc.

126 East Lincoln Avenue
Rahway, NJ 07065
United States
908 740 4000
https://www.merck.com

Sector(es)Healthcare
SectorDrug Manufacturers - General
Empleados a tiempo completo70.000

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Robert M. Davis J.D.Chairman, President & CEO6,08M6,77M1967
Ms. Caroline LitchfieldExecutive VP & CFO2,8MN/A1969
Ms. Jennifer L. ZacharyExecutive VP & General Counsel2,73M3,46M1979
Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories3,44MN/A1962
Mr. Chirfi GuindoSenior VP & Chief Marketing Officer of Human Health1,54MN/A1966
Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global ControllerN/AN/A1967
Mr. David Michael WilliamsExecutive VP and Chief Information & Digital OfficerN/AN/A1969
Mr. Peter DannenbaumVice President of Investor RelationsN/AN/AN/A
Lisa LeCointe-CephasSenior VP and Chief Ethics & Compliance OfficerN/AN/A1982
Ms. Cristal N. DowningExecutive VP and Chief Communications & Public Affairs OfficerN/AN/A1969
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Gobierno corporativo

El ISS Governance QualityScore de Merck & Co., Inc., a día 1 de marzo de 2024, es 4. Las puntuaciones base son Auditoría: 6; Tablero: 5; Derechos de los accionistas: 3; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.